Sitaxsentan (ICOS-Texas Biotechnology).
ICOS-Texas Biotechnology is developing the endothelin A (ETA) receptor antagonist, sitaxsentan, for the potential treatment of pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease and subarachnoid hemorrhage [205713], [302200]. The compound is in phase IIa trials as an iv formulation for CHF and has completed phase I safety trials as an oral formulation [272071]. Phase II/III trials for pulmonary hypertension are planned for the first quarter of 2001 [3945711]. In June 2000, ICOS and Texas Biotechnology established a joint venture to develop and commercialize endothelin antagonists [370007]. US-05591761 was issued to Texas in January 1997, covering TBC-11251 and several related isomers [2309301.
Wu-Wong
J R
JR
Abbott Laboratories, Santa Clara, CA 95054, USA. ruth.r.wuwong@abbott.com
D000818:Animals; D002986:Clinical Trials as Topic; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D007555:Isoxazoles / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D044022:Receptor, Endothelin A; D013345:Subarachnoid Hemorrhage / Q000188:drug therapy; D013876:Thiophenes / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*
D065128:Endothelin Receptor Antagonists; D007555:Isoxazoles; D044022:Receptor, Endothelin A; D013876:Thiophenes; C106276:sitaxsentan